Jonathan Schatz
@drjonschatzmd.bsky.social
Professor of Medicine, Sylvester Comprehensive Cancer Center, University of Miami. Lymphoma clinician and researcher, investigating treatment resistance and novel therapies. Opinions are my own.
Great article featuring our work on a new target for lymphoma treatment:
news.med.miami.edu/r01-grant-fo...
news.med.miami.edu/r01-grant-fo...
Exploring the Biology of Lymphoma to Identify New Drug Targets - InventUM
Sylvester researchers discovered a new role for a protein, GAK, in diffuse large B-cell lymphoma, the most common form of lymphoma.
news.med.miami.edu
September 4, 2025 at 8:21 PM
Great article featuring our work on a new target for lymphoma treatment:
news.med.miami.edu/r01-grant-fo...
news.med.miami.edu/r01-grant-fo...
This @nytimes.com article is a true public service and illustrates the requirement for high-quality journalism in a free society. To those who care only about a conclusion they want to hold onto, the facts will never matter. To the rest of us, it holds us together.
www.nytimes.com/interactive/...
www.nytimes.com/interactive/...
Opinion | The Playbook Used to ‘Prove’ Vaccines Cause Autism
Data can easily be manipulated to show a causation that doesn’t exist.
www.nytimes.com
August 19, 2025 at 1:15 PM
This @nytimes.com article is a true public service and illustrates the requirement for high-quality journalism in a free society. To those who care only about a conclusion they want to hold onto, the facts will never matter. To the rest of us, it holds us together.
www.nytimes.com/interactive/...
www.nytimes.com/interactive/...
Catch up on bispecifics with our new review, just published online. @springernature.com
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline - BioDrugs
Since blinatumomab’s approval as the first bispecific antibody (BsAb) in cancer therapy, these immunomodulatory agents have achieved substantial success in lymphoid malignancies. A decade after provis...
link.springer.com
August 2, 2025 at 9:22 PM
Catch up on bispecifics with our new review, just published online. @springernature.com
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Proud to announce online publication. Amazing work by Paola Manara and the whole Schatz lab. And congrats to @aacrjournals.bsky.social for Cancer Research Impact Factor now 16.6!
aacrjournals.org/cancerres/ar...
aacrjournals.org/cancerres/ar...
Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy
Abstract. Cancers co-opt stress response pathways to drive oncogenesis, dodge immune surveillance, and resist cytotoxic therapies. Several of these pathways also provide protection from ferroptosis, a...
aacrjournals.org
August 1, 2025 at 1:43 PM
Proud to announce online publication. Amazing work by Paola Manara and the whole Schatz lab. And congrats to @aacrjournals.bsky.social for Cancer Research Impact Factor now 16.6!
aacrjournals.org/cancerres/ar...
aacrjournals.org/cancerres/ar...
Miami Cubans get it.
April 5, 2025 at 5:49 PM
Miami Cubans get it.
Thousands in Downtown Miami at the Hands-Off protest
April 5, 2025 at 5:39 PM
Thousands in Downtown Miami at the Hands-Off protest
After receiving this score yesterday on our R01 at the National Cancer Institute, I can only express my deepest gratitude to the dedicated, hard-working employees at NIH for all they do!
April 5, 2025 at 12:16 PM
After receiving this score yesterday on our R01 at the National Cancer Institute, I can only express my deepest gratitude to the dedicated, hard-working employees at NIH for all they do!
Letter found among my late father's papers from his former post-doc mentor
April 4, 2025 at 6:40 PM
Letter found among my late father's papers from his former post-doc mentor
Reposted by Jonathan Schatz
This Seth approves.
March 23, 2025 at 11:02 PM
This Seth approves.
Amazing job by @paolamanara.bsky.social in her PhD defense this morning. Congratulations Dr. Manara, PhD.
March 24, 2025 at 5:04 PM
Amazing job by @paolamanara.bsky.social in her PhD defense this morning. Congratulations Dr. Manara, PhD.
Major Congratulations to Schatz lab graduate Caroline Coughlin matching Friday at her No. 1 choice for residency!! @bostonchildrens.bsky.social
March 24, 2025 at 5:01 PM
Major Congratulations to Schatz lab graduate Caroline Coughlin matching Friday at her No. 1 choice for residency!! @bostonchildrens.bsky.social
Our latest Preprint is up on bioRxiv. Check out exciting new insights on CAR-T resistance in LBCL
doi.org/10.1101/2025...
doi.org/10.1101/2025...
RHOA Loss of Function Impairs the IFNγ Response and Promotes CD19 Antigen Escape to Drive CAR-T Resistance in Diffuse Large B-cell Lymphoma
CD19-directed chimeric antigen receptor (CAR)-T cells are breakthrough therapies for aggressive B-cell lymphomas, but less than half of patients achieve durable responses. We previously showed through...
doi.org
March 6, 2025 at 1:15 PM
Our latest Preprint is up on bioRxiv. Check out exciting new insights on CAR-T resistance in LBCL
doi.org/10.1101/2025...
doi.org/10.1101/2025...
Reposted by Jonathan Schatz
This will have tragic consequences on medical research. #NIH ban on renewing senior scientists adds to assaults on its in-house research | Science | AAAS www.science.org/content/arti...
NIH ban on renewing senior scientists adds to assaults on its in-house research
Policy follows firings of tenure-track scientists and suspension of training programs
www.science.org
February 27, 2025 at 6:41 PM
This will have tragic consequences on medical research. #NIH ban on renewing senior scientists adds to assaults on its in-house research | Science | AAAS www.science.org/content/arti...
Our grad student Olivia Lightfuss' confocal microscopy images displayed in our Office of Graduate Studies. Nice work Liv! @austinnewsam.bsky.social @paolamanara.bsky.social
February 27, 2025 at 3:06 PM
Our grad student Olivia Lightfuss' confocal microscopy images displayed in our Office of Graduate Studies. Nice work Liv! @austinnewsam.bsky.social @paolamanara.bsky.social
Reposted by Jonathan Schatz
Tomorrow is #RareDiseaseDay! Did you know that a disease is considered rare when it affects fewer than 1 in 2,000 people? But with 7,000+ rare diseases worldwide, they collectively affect 300M+ people.
Support the ASH Research Awards Fund 🔗 https://bit.ly/3XjCFNr
#hematology #HemeSky #BloodSky
Support the ASH Research Awards Fund 🔗 https://bit.ly/3XjCFNr
#hematology #HemeSky #BloodSky
February 27, 2025 at 1:20 PM
Tomorrow is #RareDiseaseDay! Did you know that a disease is considered rare when it affects fewer than 1 in 2,000 people? But with 7,000+ rare diseases worldwide, they collectively affect 300M+ people.
Support the ASH Research Awards Fund 🔗 https://bit.ly/3XjCFNr
#hematology #HemeSky #BloodSky
Support the ASH Research Awards Fund 🔗 https://bit.ly/3XjCFNr
#hematology #HemeSky #BloodSky
Study section I was scheduled to serve on Thursday and Friday this week, countless hours spent in preparation by me and the rest of the members, canceled today with no explanation given. Why would Putin have ordered this?
February 26, 2025 at 1:00 AM
Study section I was scheduled to serve on Thursday and Friday this week, countless hours spent in preparation by me and the rest of the members, canceled today with no explanation given. Why would Putin have ordered this?
With Sylvester Director Stephen Nimer at the 15 Dolphins Cancer Challegne today. 99 miles!
A great way to support Cancer Research in Desperate Times!
dolphinscancerchallenge.com/index.cfm?fu...
A great way to support Cancer Research in Desperate Times!
dolphinscancerchallenge.com/index.cfm?fu...
February 22, 2025 at 9:31 PM
With Sylvester Director Stephen Nimer at the 15 Dolphins Cancer Challegne today. 99 miles!
A great way to support Cancer Research in Desperate Times!
dolphinscancerchallenge.com/index.cfm?fu...
A great way to support Cancer Research in Desperate Times!
dolphinscancerchallenge.com/index.cfm?fu...
Reposted by Jonathan Schatz
February 21, 2025 at 2:00 AM
Thanks to the Cutaneous Lymphoma Foundation for listing our multidisciplinary skin lymphoma clinic. This clinic staffed by me and Georgios Pongas from hematology and Scott Elman from dermatology is an incredible resource for patients affected by these diseases!
www.clfoundation.org/sylvester-co...
www.clfoundation.org/sylvester-co...
Sylvester Comprehensive Cancer Center
www.clfoundation.org
February 3, 2025 at 3:14 PM
Thanks to the Cutaneous Lymphoma Foundation for listing our multidisciplinary skin lymphoma clinic. This clinic staffed by me and Georgios Pongas from hematology and Scott Elman from dermatology is an incredible resource for patients affected by these diseases!
www.clfoundation.org/sylvester-co...
www.clfoundation.org/sylvester-co...
BLUETORIAL 6) Read our paper for the fascinating mechanisms of how this all works. Incredible work by our first and many contributing authors over the past several years!
February 3, 2025 at 2:10 PM
BLUETORIAL 6) Read our paper for the fascinating mechanisms of how this all works. Incredible work by our first and many contributing authors over the past several years!
We're excited to announce online publication of our new article in Blood Cancer Journal @natureportfolio.nature.com
Major Congratulations to our co-first authors Caroline Coughlin and Dhanvantri (Davi) Chahar.
"Bluetorial" overview follows in my replies.
www.nature.com/articles/s41...
Major Congratulations to our co-first authors Caroline Coughlin and Dhanvantri (Davi) Chahar.
"Bluetorial" overview follows in my replies.
www.nature.com/articles/s41...
Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax - Blood Cancer Journal
Blood Cancer Journal - Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax
www.nature.com
February 3, 2025 at 1:56 PM
We're excited to announce online publication of our new article in Blood Cancer Journal @natureportfolio.nature.com
Major Congratulations to our co-first authors Caroline Coughlin and Dhanvantri (Davi) Chahar.
"Bluetorial" overview follows in my replies.
www.nature.com/articles/s41...
Major Congratulations to our co-first authors Caroline Coughlin and Dhanvantri (Davi) Chahar.
"Bluetorial" overview follows in my replies.
www.nature.com/articles/s41...
Reposted by Jonathan Schatz
It’s an open secret among medical professionals: Many drugs maintain their ability to combat ailments well after their expiration date. One pharmacist says he sometimes takes home expired OTC medicine so he and his family can use it.
(Published 2017, but there's no expiration date for this story)
(Published 2017, but there's no expiration date for this story)
The Myth of Drug Expiration Dates
Hospitals and pharmacies are required to toss expired drugs, no matter how expensive or vital. Meanwhile the FDA has long known that many remain safe and potent for years longer.
propub.li
January 27, 2025 at 4:00 AM
It’s an open secret among medical professionals: Many drugs maintain their ability to combat ailments well after their expiration date. One pharmacist says he sometimes takes home expired OTC medicine so he and his family can use it.
(Published 2017, but there's no expiration date for this story)
(Published 2017, but there's no expiration date for this story)
Great overview on risks and reasons for secondary malignancies post-CAR-T therapies. Contribution of the CAR itself is minimal, despite the FDA's black box warning. Great work by Sylvester's Jay Spiegel.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
December 16, 2024 at 1:41 PM
Great overview on risks and reasons for secondary malignancies post-CAR-T therapies. Contribution of the CAR itself is minimal, despite the FDA's black box warning. Great work by Sylvester's Jay Spiegel.
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
